Advanced Materials IP Licensing Platform
Four patent families spanning targeted drug delivery, real-time oxygen sensing, industrial carbon capture, and next-generation satellite materials. Cisplatin-validated. Ready for licensing.
About the Platform
Metal-organic frameworks are crystalline, porous materials with unparalleled tunability. We have built a portfolio of four interlocking patent families — each targeting a distinct, high-value industry — all sharing the same foundational MOF science.
Licenses may be structured as single-family, multi-family, or full portfolio. All families are available for exclusive, co-exclusive, or non-exclusive arrangements. Full characterization data, synthesis protocols, and in vitro cell data available under NDA.
Patent Portfolio
Azobenzene-based MOF platform triggers drug release exclusively in hypoxic tumor microenvironments via azo-bond reductive cleavage. Cisplatin-validated with avg 45.86% drug loading and avg 84.82% encapsulation efficiency (3 independent samples). 1,044.6 m²/g BET surface area. PXRD confirms structural collapse onset at 1 hour under hypoxia; full stability under normoxia.
Phosphorescent Cu(I) complexes and pyridylimine-functionalized MOFs detect intratumoral oxygen tension in real time via phosphorescence quenching. Up to 85% quenching within 20 minutes. Liposome-MOF conjugate system enables closed-loop theranostics — simultaneous tumor mapping and triggered drug release from a single construct.
Six MOF formula families — imidazolate ZIFs, amino-functionalized frameworks, MOF-74 DOBDC series, mixed-metal MOFs, transition metal organometallics, and N-heterocyclic carbene complexes — targeting CO₂ capture from power generation, cement, steel, refinery, and chemical manufacturing sources.
Five MOF formula families engineered for extreme space environments: lanthanide-based (Gd/Hf) for neutron and gamma-ray shielding, Zr-based UiO series for thermal stability to 500°C, Zn-MOFs for lightweight gas storage, iron/chromium porphyrin MOFs for catalysis, and ZIFs for CO₂ scrubbing in manned missions.
Validated Proof of Concept
Experimental Data
Cisplatin (MW 300.05, Cl₂H₆N₂Pt) loaded at 37°C, 200 RPM, 48 hr incubation. Analysis by UV-Vis spectroscopy.
| Sample | Encapsulated | DL % | EE % |
|---|---|---|---|
| Sample 1 | 3.91 mg | 43.87% | 78.15% |
| Sample 2 | 4.43 mg | 46.99% | 88.66% |
| Sample 3 | 4.38 mg | 46.71% | 87.65% |
| Timepoint | Normoxia | Hypoxia | Fold Δ |
|---|---|---|---|
| 30 min | 0.175 mg | 1.537 mg | 8.8× |
| 2 hr | 0.356 mg | 2.626 mg | 7.4× |
| 24 hr | 0.965 mg | 4.117 mg | 4.3× |
| 72 hr | 2.306 mg | 5.422 mg | 2.4× |
Development Stage
All four families are available for licensing now. Drug delivery and oxygen sensing have the deepest data packages; carbon capture and satellite are IP-stage with compelling structural frameworks.
◆ TEAL = active / complete · ◆ GOLD = near-term / in progress · ○ OUTLINE = planned
Licensing
Every licensing structure is negotiable. We can accommodate single-family, multi-family, or full portfolio deals across any geography and field of use.
Single licensee per field of use. Upfront fee + milestone payments + royalty on net sales. Full technical support from inventors included.
Up to two licensees sharing rights across defined indication areas or geographies. Preferred for multi-indication platforms.
Field-of-use restricted access for multiple partners. Ideal for platform technologies being deployed across distinct verticals (e.g., oncology + industrial CCS).
Time-limited exclusivity window for diligence, feasibility studies, and IND-enabling work before committing to full license terms.
Get in Touch
Full synthesis protocols, characterisation data, and experimental results available under NDA. Reach David directly — responses within 48 hours.